Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.45 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925340 | 0.85 | MAP4K4 (0.45) | MAP4K4MINK1TNIKEGLN2GSK3B | |
| SCHEMBL1131431 | 0.83 | SLC6A2 (0.46) | GSK3BKMT2A | |
| SCHEMBL6668052 | 0.81 | EGLN1 (0.51) | EGLN1MAP4K4MINK1TNIKEGLN2 | |
| SCHEMBL19230093 | 0.77 | DEGS1 (0.52) | EGLN1EGLN2MEN1KMT2AXDH | |
| SCHEMBL1417979 | 0.75 | HDAC2 (0.57) | EGLN2GSK3BMEN1KMT2AHDAC6 | |
| SCHEMBL6827568 | 0.72 | SLC22A12 (0.54) | MAP4K4EGLN2GSK3BXDHKDM1A | |
| SCHEMBL24023216 | 0.72 | PLK1 (0.44) | MEN1KMT2AROCK2ROCK1HDAC6 | |
| SCHEMBL1132139 | 0.71 | SLC6A2 (0.48) | KMT2AROCK2ROCK1 | |
| SCHEMBL28787158 | 0.71 | EGFR (0.52) | MEN1KMT2AXDHROCK2 | |
| SCHEMBL6825145 | 0.69 | EGLN2 (0.42) | MAP4K4MINK1TNIKEGLN2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1429759-A4 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6803374-B2 | INHIBIT THE RNA-DEPENDENT RNA POLYMERASE (RDRP) ENCODED BY HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| EP-1429759-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | Bristol-Myers Squibb Company (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040067976-A1 | Compounds useful for treating Hepatitis C virus | PRIESTLEY ELDON SCOTT (US) | 2004-04-08 | — | — | US | disclosed |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-17 | — | — | US | disclosed |
| WO-2003026587-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067976-A1 | Compounds useful for treating Hepatitis C virus | OAT, HAVCR2, GOT1 | EGLN1 574/4885MAP4K4 4022/4885MINK1 2908/4885 |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | OAT, HAVCR2, GOT1 | EGLN1 574/4885MAP4K4 4022/4885MINK1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.